Australia’s emerging psychedelic medicine sector is warning that proposed federal tax reforms could undermine the country’s ability to attract investment into one of the world’s fastest growing areas of mental health innovation.
The concerns come at a pivotal moment for an industry that has spent years positioning Australia as a global leader in psychedelic research, clinical trials and treatment development.
While debate over the Federal Government’s May Budget measures has largely centred on broader economic impacts, founders, investors and advisors within the psychedelic ecosystem argue the consequences for early-stage innovation could be significant.
Their concern is not simply about taxation.
It is about whether Australia can retain the companies, intellectual property and investment capital needed to build a globally competitive psychedelic medicine industry.
For a sector that relies heavily on long-term investment and scientific risk-taking, even small shifts in investor sentiment can have major consequences.
A Sector Built on Long-Term Capital
Unlike traditional businesses, psychedelic medicine companies often spend years developing products and services before generating meaningful revenue.
Clinical trials must be conducted. Regulatory approvals secured. Scientific evidence established. Treatment models refined. Intellectual property protected.
The process can take five to ten years and require millions, sometimes tens of millions, of dollars before a company reaches commercial scale.
As a result, the sector depends heavily on patient investors willing to fund high-risk ventures in the hope of future returns.
For many founders, access to capital is not simply about growth, it is about survival.
Investors considering these opportunities rarely evaluate science alone. They assess taxation frameworks, corporate structures, intellectual property protections, regulatory certainty and future exit opportunities before deciding where to allocate capital.
Industry participants argue that if Australia becomes less attractive relative to competing jurisdictions, investment decisions will inevitably follow.
Why Founders Are Looking Overseas
Just a few years ago, psychedelic medicine was being promoted as one of the world’s most promising emerging healthcare sectors.
Depending on the forecast, analysts have projected the global psychedelic therapeutics market could exceed US$10 billion annually within the next decade, with opportunities extending far beyond medicines themselves.
Investors have poured capital into clinic networks, therapist training programs, digital health platforms, artificial intelligence tools, patient management systems and intellectual property portfolios designed to support the delivery of psychedelic-assisted therapies.
That growth narrative attracted entrepreneurs, researchers and investors across Australia.
But some industry participants now worry that uncertainty around Australia’s future investment environment risks changing the equation.
Consider a founder who spends five years building a psychedelic healthcare technology company.
They invest personal savings, recruit staff, raise seed funding from angel investors and develop proprietary software designed to support psychiatrists delivering psychedelic-assisted therapy.
Like many startup founders, their long-term objective is to build a valuable business that may eventually attract acquisition interest from a larger healthcare company, pharmaceutical group or international technology provider.
That future exit opportunity is often what justifies years of financial risk and personal sacrifice.
If investors believe future tax settings reduce the attractiveness of those outcomes, they may become less willing to fund similar ventures.
The consequence is not simply fewer investments. The consequence may be that future companies are incorporated in London, Singapore, New Zealand or Delaware from day one, with intellectual property, future capital raises and eventual acquisition value held offshore rather than in Australia.
Australia’s First-Mover Advantage
The timing is particularly significant because Australia has spent much of the past decade building a genuine competitive advantage in psychedelic medicine.
Researchers from leading universities have contributed to internationally recognised studies investigating psilocybin, MDMA and related compounds for conditions including treatment-resistant depression, post-traumatic stress disorder and end-of-life anxiety.
Australia’s clinical trial ecosystem has also gained international recognition, supported by experienced investigators, robust regulatory frameworks and growing institutional interest.
The country’s global profile increased substantially in 2023 when authorised psychiatrists were permitted to prescribe psilocybin and MDMA under tightly controlled circumstances for specific mental health conditions.
The decision positioned Australia among the first countries in the world to establish a regulated pathway for psychedelic-assisted therapies.
For many observers, it signalled that Australia intended to become a serious participant in what could become one of the most important developments in mental healthcare in decades.
The challenge now is ensuring that scientific leadership translates into commercial leadership.
Global Competition Is Intensifying
The psychedelic medicine sector is no longer viewed as a fringe scientific experiment.
Major pharmaceutical companies, institutional investors and healthcare providers are increasingly monitoring developments in the field as evidence supporting psychedelic-assisted therapies continues to grow.
Countries including the United States, Canada, the United Kingdom and several European nations continue investing heavily in research, infrastructure and commercial development.
Many of these jurisdictions are actively competing to attract biotechnology companies, venture capital and intellectual property.
Australia’s advantage has never been its size. Its advantage has been its ability to move quickly, support innovative research and create regulatory pathways that encourage responsible development.
Industry leaders fear that advantage could be weakened if capital begins flowing elsewhere. Once intellectual property, corporate headquarters and investment ecosystems relocate, they are often difficult to attract back.
The Risk of Losing More Than Capital
Industry stakeholders argue that Australia has a rare opportunity.
The country was among the first in the world to create a regulated pathway for psychiatrist-prescribed psychedelic medicines. It has respected universities, experienced researchers and a growing network of clinics and trial sites.
What Australia lacks is scale, that means attracting capital remains critical. Some founders warn that if investment conditions become less competitive, Australia could find itself in a familiar position. The research happens locally. The discoveries happen locally.
But the companies that ultimately commercialise those discoveries emerge elsewhere.
The concern is not merely a loss of investment.
It is the potential loss of high-value jobs, intellectual property ownership, future tax revenue and globally competitive healthcare businesses.
In other words, Australia risks becoming the laboratory where ideas are born rather than the place where successful companies are ultimately built.
What Governments Could Do
Industry participants are not necessarily calling for special treatment. Instead, many argue that policymakers should focus on strengthening Australia’s position as a destination for innovation capital.
Potential measures could include expanding R&D tax incentives, increasing support for biotechnology commercialisation programs, streamlining clinical trial approvals and developing targeted funding initiatives for emerging mental health technologies.
Some also believe governments should actively promote Australia as a global destination for psychedelic medicine research, treatment innovation and healthcare technology development.
Supporters argue that Australia’s regulatory leadership has already created a significant competitive advantage.
The challenge now is ensuring that capital remains onshore long enough for Australian companies to scale and succeed.
A Defining Moment
The psychedelic medicine industry remains relatively small today, but its future potential is substantial.
The therapies currently being investigated have the potential to transform treatment options for millions of people living with depression, PTSD, addiction and other serious mental health conditions.
The economic opportunity accompanying those breakthroughs could be equally significant.
Australia has already demonstrated scientific capability, regulatory leadership and growing clinical expertise.
What remains uncertain is whether the country can also become the preferred destination for the capital required to build globally competitive companies.
As policymakers continue debating the future of Australia’s investment landscape, founders, researchers and investors across the psychedelic sector will be watching closely.
Because in a global market, capital is mobile.
And if Australia wants to become a genuine hub for next-generation mental health innovation, many in the industry argue it must ensure that the companies built from Australian science have compelling reasons to remain Australian.
Otherwise, Australia may end up funding the research while other nations capture the rewards.
